S&P 500   5,071.42 (+0.04%)
DOW   38,958.07 (-0.28%)
QQQ   437.13 (+0.13%)
AAPL   181.41 (+0.14%)
MSFT   406.78 (-0.19%)
META   485.13 (+0.70%)
GOOGL   137.98 (+0.30%)
AMZN   174.29 (-0.25%)
TSLA   203.10 (+1.86%)
NVDA   789.33 (-0.20%)
NIO   5.83 (+3.19%)
AMD   177.34 (+0.76%)
BABA   77.60 (+1.42%)
T   16.58 (-0.12%)
F   12.03 (+0.67%)
MU   90.87 (+1.58%)
CGC   3.50 (+0.86%)
GE   154.34 (-0.28%)
DIS   108.14 (+0.43%)
AMC   4.67 (+4.94%)
PFE   26.91 (-0.99%)
PYPL   59.88 (+0.93%)
XOM   104.12 (-0.12%)
S&P 500   5,071.42 (+0.04%)
DOW   38,958.07 (-0.28%)
QQQ   437.13 (+0.13%)
AAPL   181.41 (+0.14%)
MSFT   406.78 (-0.19%)
META   485.13 (+0.70%)
GOOGL   137.98 (+0.30%)
AMZN   174.29 (-0.25%)
TSLA   203.10 (+1.86%)
NVDA   789.33 (-0.20%)
NIO   5.83 (+3.19%)
AMD   177.34 (+0.76%)
BABA   77.60 (+1.42%)
T   16.58 (-0.12%)
F   12.03 (+0.67%)
MU   90.87 (+1.58%)
CGC   3.50 (+0.86%)
GE   154.34 (-0.28%)
DIS   108.14 (+0.43%)
AMC   4.67 (+4.94%)
PFE   26.91 (-0.99%)
PYPL   59.88 (+0.93%)
XOM   104.12 (-0.12%)
S&P 500   5,071.42 (+0.04%)
DOW   38,958.07 (-0.28%)
QQQ   437.13 (+0.13%)
AAPL   181.41 (+0.14%)
MSFT   406.78 (-0.19%)
META   485.13 (+0.70%)
GOOGL   137.98 (+0.30%)
AMZN   174.29 (-0.25%)
TSLA   203.10 (+1.86%)
NVDA   789.33 (-0.20%)
NIO   5.83 (+3.19%)
AMD   177.34 (+0.76%)
BABA   77.60 (+1.42%)
T   16.58 (-0.12%)
F   12.03 (+0.67%)
MU   90.87 (+1.58%)
CGC   3.50 (+0.86%)
GE   154.34 (-0.28%)
DIS   108.14 (+0.43%)
AMC   4.67 (+4.94%)
PFE   26.91 (-0.99%)
PYPL   59.88 (+0.93%)
XOM   104.12 (-0.12%)
S&P 500   5,071.42 (+0.04%)
DOW   38,958.07 (-0.28%)
QQQ   437.13 (+0.13%)
AAPL   181.41 (+0.14%)
MSFT   406.78 (-0.19%)
META   485.13 (+0.70%)
GOOGL   137.98 (+0.30%)
AMZN   174.29 (-0.25%)
TSLA   203.10 (+1.86%)
NVDA   789.33 (-0.20%)
NIO   5.83 (+3.19%)
AMD   177.34 (+0.76%)
BABA   77.60 (+1.42%)
T   16.58 (-0.12%)
F   12.03 (+0.67%)
MU   90.87 (+1.58%)
CGC   3.50 (+0.86%)
GE   154.34 (-0.28%)
DIS   108.14 (+0.43%)
AMC   4.67 (+4.94%)
PFE   26.91 (-0.99%)
PYPL   59.88 (+0.93%)
XOM   104.12 (-0.12%)

Krystal Biotech (KRYS) Stock Forecast & Price Target

$159.07
+2.07 (+1.32%)
(As of 10:21 AM ET)

Krystal Biotech Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$148.78
-6.47% Downside
High Forecast$180.00
Average Forecast$148.78
Low Forecast$118.00
TypeCurrent Forecast
2/27/23 to 2/27/24
1 Month Ago
1/28/23 to 1/28/24
3 Months Ago
11/29/22 to 11/29/23
1 Year Ago
2/27/22 to 2/27/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$148.78$148.78$146.56$106.75
Predicted Upside-6.47% Downside37.96% Upside37.13% Upside42.15% Upside
Get Krystal Biotech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.


KRYS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KRYS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Krystal Biotech Stock vs. The Competition

TypeKrystal BiotechMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside-5.24% Downside1,856.38% Upside8.21% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/27/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
12/13/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$160.00 ➝ $180.00+59.60%
11/20/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$160.00+53.61%
10/12/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$160.00+41.59%
9/7/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$154.00+24.19%
8/7/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$148.00 ➝ $153.00+41.00%
8/7/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$139.00+28.10%
5/24/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$102.00 ➝ $145.00+21.72%
5/22/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$101.00 ➝ $130.00+29.55%
5/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$105.00 ➝ $118.00+22.84%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:41 AM ET.












KRYS Price Target - Frequently Asked Questions

What is Krystal Biotech's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Krystal Biotech stock is Buy based on the current 9 buy ratings for KRYS. The average twelve-month price prediction for Krystal Biotech is $148.78 with a high price target of $180.00 and a low price target of $118.00. Learn more on KRYS's analyst rating history.

Do Wall Street analysts like Krystal Biotech more than its competitors?

Analysts like Krystal Biotech more than other Medical companies. The consensus rating for Krystal Biotech is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how KRYS compares to other companies.

Does Krystal Biotech's stock price have much upside?

According to analysts, Krystal Biotech's stock has a predicted upside of 37.96% based on their 12-month stock forecasts.

What analysts cover Krystal Biotech?

Krystal Biotech has been rated by Cantor Fitzgerald, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:KRYS) was last updated on 2/27/2024 by MarketBeat.com Staff